Cystic Fibrosis & Physical Development: Growth, Puberty, Bone, and Muscle Health

Cystic fibrosis (CF), caused by CFTR mutations, disrupts epithelial chloride/bicarbonate transport → thick mucus, chronic infection, inflammation, and multisystem dysfunction that profoundly affects growth and development.

Growth Impairment

  • Malabsorption: Pancreatic insufficiency (85–90%) → fat/protein malabsorption → steatorrhea, fat-soluble vitamin (A,D,E,K) deficiency. Despite enzyme replacement (PERT), coefficient of fat absorption ~85–90%.
  • Increased energy expenditure: Work of breathing, chronic inflammation, infection → resting energy expenditure 110–150% predicted.
  • Endocrine dysregulation: CF-related diabetes (CFRD) ~20% adolescents, 40–50% adults; growth hormone/IGF-1 resistance; hypothalamic-pituitary axis alterations.
  • Outcome: Reduced height/weight Z-scores; delayed bone age. Aggressive nutrition (120–150% RDI) + PERT + CFTR modulators (elexacaftor/tezacaftor/ivacaftor) improve trajectories.

Pubertal Delay

  • Mean onset delayed 1–2 years (both sexes).
  • Mechanisms: Undernutrition → low leptin → GnRH suppression; chronic inflammation; CFRD; glucocorticoid use.
  • Consequences: Reduced peak bone mass, psychosocial distress.
  • Monitoring: Tanner staging, growth velocity, bone age annually from age 10.

Bone Health

  • Osteopenia/osteoporosis: 20–25% adults; fractures ↑ 4–6x.
  • Risk factors: Vitamin D/K malabsorption, low weight, hypogonadism, glucocorticoids, inflammation (RANKL/OPG), immobility.
  • Screening: DXA (Z-scores) from age 8–10; vertebral fracture assessment.
  • Management: Optimize Ca²⁺/vitamin D, weight-bearing exercise, gonadal steroids if hypogonadal, bisphosphonates if fractures/very low Z-score.

Muscle & Body Composition

  • Sarcopenia: Reduced muscle mass/strength (↓protein synthesis, ↑catabolism, inactivity).
  • Altered composition: Higher fat mass %, lower lean mass — "skinny-fat" phenotype despite normal BMI.
  • Exercise training (aerobic + resistance) improves muscle function, lung clearance, quality of life.

CFTR Modulators: Changing the Landscape

Highly effective modulator therapy (HEMT) for eligible mutations (≥90% patients) → ↑weight, ↑lung function, ↓exacerbations, ↑pancreatic function, potential normalization of growth/puberty trajectories if started early.

Multidisciplinary CF center care (pulmonology, nutrition, endocrinology, PT, psychosocial) with quarterly visits is standard for optimizing development.

Bones, Joints & Muscles - Related Articles